Insider Transactions in Q1 2023 at Atara Biotherapeutics, Inc. (ATRA)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Jakob Dupont EVP, Head of R&D |
SELL
Open market or private sale
|
Direct |
5,074
-1.72%
|
$15,222
$3.63 P/Share
|
|
Mar 02
2023
|
Utpal Koppikar Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,871
-3.64%
|
$20,613
$3.63 P/Share
|
|
Mar 02
2023
|
Amar Murugan EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,221
-1.49%
|
$12,663
$3.63 P/Share
|
|
Mar 02
2023
|
Pascal Touchon President and CEO |
SELL
Open market or private sale
|
Direct |
15,679
-2.05%
|
$47,037
$3.63 P/Share
|
|
Mar 01
2023
|
Amar Murugan EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
155,375
+35.4%
|
-
|
|
Mar 01
2023
|
Jakob Dupont EVP, Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
141,328
+32.33%
|
-
|
|
Mar 01
2023
|
Charlene A. Banard EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
139,700
+32.13%
|
-
|
|
Mar 01
2023
|
Pascal Touchon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
324,711
+29.76%
|
-
|
|
Feb 07
2023
|
Utpal Koppikar Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,485
-1.3%
|
$12,425
$5.46 P/Share
|